护城河对比
最多三家已覆盖的公司，逐项对照。每一项判断都是人工编辑的判断，而非公司披露的数字——并且每一项都附有其引用依据。
| Micron | Wistron | Eli Lilly and Company | |
|---|---|---|---|
| 护城河评级 | 窄 Micron sits in a three-firm DRAM oligopoly (with Samsung and SK hynix), holds "over 60,000 patents" and leading-edge process technology (industry-first 1-gamma EUV DRAM node in FY2025), yet its FY2025 10-K concedes competitors "may use aggressive pricing" and "may have a larger market share," and consolidated gross margin swung from negative 9% (FY2023) to 40% (FY2025) — a real but commodity-cyclical, non-durable advantage. | 无 2025 年年报（向 TWSE 提交的英文译本，2026-04-28）显示的是没有受保护回报的规模：营收 NT$2.1865 trillion，增长 108%，毛利率 6.1%，合并营业利润率 3.6%，毛利增长 59.33%，而净营收增长 108.39%。年报自列的不利因素以 "Intense Price Competition and Declining Gross Profit Margins" 开篇，并称 IT 行业 "with its relatively low barriers to entry, has attracted numerous manufacturers, leading to fierce competition"；其主要买家表显示 Buyer A、Buyer E 和 Buyer I 分别占 2025 年净销售额的 39.32%、21.21% 和 12.81%。这是一家规模庞大、具备竞争力的在位企业，而其自身申报文件承认进入壁垒相对较低：无法认定存在护城河。 | 宽 Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. |
| 护城河类型 | 无形资产与知识产权 The 10-K roots Micron's edge in proprietary technology and IP: "over 60,000 patents" granted as of Aug 28, 2025, "significant investments to develop proprietary product and process technology," the industry's first 1-gamma (EUV) DRAM node, ninth-generation G9 NAND, and HBM4 samples to key AI customers. | 无 年报的 "Competitive Niches" 章节列出的是经营能力而非持久壁垒："over 5,600 people" 的研发团队，位于台湾、美国、中国、墨西哥、捷克、越南和马来西亚的制造基地，精益制造、产品质量、供应商关系、全球物流以及经验丰富的管理团队。这些都不构成专利地位或客户锁定效应：2025 年研发费用占营收的 1.43%，公司报告 2025 年获得 120 项美国专利和 122 项台湾专利授权，而该章节对品牌客户 "each comprising an equal share of our sales" 的描述，旁边就是一张单一买家占 2025 年净销售额 39.32% 的主要买家表。 | 无形资产与知识产权 Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. |
| 领先地位 | 并列领先者 A member of the three-supplier DRAM oligopoly and at the technology frontier (industry-first 1-gamma EUV node), but the smallest of the three by share — the 10-K acknowledges competitors "may have a larger market share" — and a later entrant scaling up in HBM behind SK hynix and Samsung. | 势均力敌 Citing MIC (February 2026), the report puts the Company at approximately 18% of the roughly 135,350K notebooks, 24% of the 39,711K desktops and 22% of the 12,370K servers manufactured in Taiwan in 2025, and lists it among the major Taiwan ODMs in every category it charts (notebooks with Quanta, Compal, Inventec and Pegatron; servers with Hon Hai, Quanta, Inventec and MiTAC). It describes this only as "considerable market competitiveness" and claims no first-place rank. | 并列领先者 Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. |
| 定价权 | 弱 Memory is a commodity with cyclical ASPs: the 10-K flags "volatility in average selling prices" and competitors' "aggressive pricing" as key risks, and consolidated gross margin swung from -9% (FY2023) to 22% (FY2024) to 40% (FY2025), marking Micron largely as a cyclical price-taker; contract-based, supply-tight HBM is a partial exception. | 弱 2025 gross profit margin was 6.1% and consolidated operating profit margin 3.6%; gross profit rose 59.33% while net revenues rose 108.39%, so the margin narrowed. The report's first unfavorable factor is "Intense Price Competition and Declining Gross Profit Margins", and three buyers accounted for 39.32%, 21.21% and 12.81% of 2025 net sales. | 中等 Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. |
| 综述 | Micron is one of only three scaled DRAM suppliers (with Samsung and SK hynix) and a leading-edge NAND maker, defended by proprietary product and process technology and more than 60,000 granted patents. In FY2025 it shipped the industry's first 1-gamma (EUV) DRAM production node and sampled HBM4 36GB 12-high to multiple key customers for next-generation AI platforms, evidencing process-technology leadership in AI memory (FY2025 10-K). | Wistron 是一家台湾 ODM，根据其 2025 年年报，其业务 "primarily covers the R&D, manufacturing, testing and after-sales services"，对象包括服务器与 AI 计算设备、笔记本电脑、台式机、显示器及其他电子产品，3C 电子产品占 2025 年销售额的 98.5%。营收增长逾一倍至 NT$2.1865 trillion，董事长致辞将其称为 "triple-digit percentage growth in revenue from AI and general-purpose servers"；年报还引用 MIC 数据，显示 2025 年公司约占台湾制造笔记本电脑的 18%、台式机的 24% 和服务器的 22%。与此相对，毛利率为 6.1%，年报自列的不利因素包括激烈的价格竞争、毛利率下滑以及相对较低的进入壁垒，且三家买家分别占 2025 年净销售额的 39.32%、21.21% 和 12.81%。长期计划是提高 AI 计算设备和服务器等高毛利产品的占比，制造政策则将自动化与 AI 驱动的智能制造瞄准 "higher-complexity, technically demanding product segments — expanding gross margins"——这是一条明示的通往优势的路径，而非优势已经存在的证据。 | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." |
| 产业链位置 | US-based supplier of the memory tier of the AI stack — DRAM, HBM and NAND; the 10-K notes cloud servers for AI and data-centric workloads "require significantly increasing quantities of DRAM, including HBM," and Micron sampled HBM4 to power next-generation AI platforms. | Contract designer-manufacturer for brand and cloud customers: the report describes "professional OEM services supporting clients with world renowned brands", lists CPUs, SSDs and DRAM as main materials, and among its 2025 R&D results lists GPU servers supporting NVIDIA B300, AMD MI355 and Intel Gaudi 3. | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. |
| 产品（份额 / 壁垒） |
|
|
|
| 长周期投票 | +0.05 权重 0.20 · 群体判断 bullish 编辑先验，未经回测。 | -0.06 权重 0.20 · 群体判断 neutral 编辑先验，未经回测。 | +0.30 权重 0.20 · 群体判断 neutral 编辑先验，未经回测。 |